Topiramate (Epilepsy) updated on 04-22-2025

Psychomotor developmental disorders/delay

R analysis
id Study   Lib. in paper Exposition period    Study type  Control type 
 
Tags OR 95%CI x1/n1 x0/n0 no cases no exposed ROB Ref.
S19436
R82833
Honybun (Controls exposed to LTG) (Topiramate) (Epilepsy), 2026 Processing Speed Index (Assesses psychomotor speed across time-based tasks) - Wechsler Intelligence Scale - Children aged 3–18 years (mean age about 10 years) during pregnancy (anytime or not specified) prospective cohort exposed to other treatment, sick excluded Adjustment: No extrapolated (cont. endpoint) 2.21 [0.59;8.24]
excluded (control group)
-/11   -/23 - 11
ref
S19440
R82873
Honybun (Controls unexposed, sick) (Topiramate) (Epilepsy), 2026 Processing Speed Index (Assesses psychomotor speed across time-based tasks) - Wechsler Intelligence Scale - Children aged 3–18 years (mean age about 10 years) during pregnancy (anytime or not specified) prospective cohort unexposed, sick Adjustment: No extrapolated (cont. endpoint) 2.78 [0.86;9.05] -/19   -/19 - 19
ref
S19474
R83124
Straub (Controls unexposed, sick) (Topiramate) (Epilepsy), 2026 Coordination disorders - ICD-10 codes: F82 - Mean follow up (full cohort): 3.4 years during pregnancy (anytime or not specified) retrospective cohort (claims database) unexposed, sick Adjustment: Yes 0.59 [0.26;1.33] -/961   91/8,887 - 961
ref
S16795
R70485
Thomas b (Controls exposed to LTG), 2022 The motor development quotient (MODQ) - The developmental assessment scale for Indian infants (DASII) - Between 12-24 months of age (mean (SD): 15.3 (3.9) months)) during pregnancy (anytime or not specified) prospective cohort exposed to other treatment, sick excluded Adjustment: No extrapolated (cont. endpoint) 1.38 [0.27;6.90]
excluded (control group)
-/6   -/26 - 6
ref
S16796
R70487
Thomas b (Controls unexposed, sick), 2022 The motor development quotient (MODQ) - The developmental assessment scale for Indian infants (DASII) - Between 12-24 months of age (mean (SD): 15.3 (3.9) months)) during pregnancy (anytime or not specified) prospective cohort unexposed, sick Adjustment: No extrapolated (cont. endpoint) 0.51 [0.11;2.27] -/6   -/110 - 6
ref
Total 3 studies 0.94 [0.33;2.70] 0 986
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives

Forest plot

StudyTE95% CIn casesn exposedweightROBABCDEF Honybun (Controls unexposed, sick) (Topiramate) (Epilepsy), 2026Honybun, 2026 1 2.78[0.86; 9.05]-1933%ROB confusion: criticalROB selection: lowROB classification: moderateROB missing: criticalROB mesure: lowROB reporting: moderate Straub (Controls unexposed, sick) (Topiramate) (Epilepsy), 2026Straub, 2026 2 0.59[0.26; 1.33]-96142%ROB confusion: seriousROB selection: lowROB classification: moderateROB missing: unclearROB mesure: criticalROB reporting: moderate Thomas b (Controls unexposed, sick), 2022Thomas b, 2022 3 0.51[0.11; 2.27]-626%ROB confusion: criticalROB selection: lowROB classification: moderateROB missing: unclearROB mesure: lowROB reporting: moderate Total (3 studies) I2 = 61% 0.94[0.33; 2.70]-9860.210.01.0ROB: A: confounding, B: selection, C: classification, D: missing, E: measurement, F: reportinglow,moderate,serious,critical,unclear,

1: Controls unexposed, sick) (Topiramate) (Epilepsy; 2: Controls unexposed, sick) (Topiramate) (Epilepsy; 3: Controls unexposed, sick;

Sensitivity analysis

SubsetTE95% CIn casesn exposedkI2 Type of studies cohort studiescohort studies 0.94[0.33; 2.70]-98661%NAHonybun (Controls unexposed, sick) (Topiramate) (Epilepsy), 2026 Straub (Controls unexposed, sick) (Topiramate) (Epilepsy), 2026 Thomas b (Controls unexposed, sick), 2022 3 case control studiescase control studies 0 Type of controls unexposed, sickunexposed, sick 0.94[0.33; 2.70]-98661%NAHonybun (Controls unexposed, sick) (Topiramate) (Epilepsy), 2026 Straub (Controls unexposed, sick) (Topiramate) (Epilepsy), 2026 Thomas b (Controls unexposed, sick), 2022 3 Tags Adjustment   - No  - No 1.28[0.24; 6.69]-2567%NAHonybun (Controls unexposed, sick) (Topiramate) (Epilepsy), 2026 Thomas b (Controls unexposed, sick), 2022 2   - Yes  - Yes 0.59[0.26; 1.33]-961 -NAStraub (Controls unexposed, sick) (Topiramate) (Epilepsy), 2026 1 extrapolated (cont. endpoint)extrapolated (cont. endpoint) 1.28[0.24; 6.69]-2567%NAHonybun (Controls unexposed, sick) (Topiramate) (Epilepsy), 2026 Thomas b (Controls unexposed, sick), 2022 2 All studiesAll studies 0.94[0.33; 2.70]-98661%NAHonybun (Controls unexposed, sick) (Topiramate) (Epilepsy), 2026 Straub (Controls unexposed, sick) (Topiramate) (Epilepsy), 2026 Thomas b (Controls unexposed, sick), 2022 30.210.01.0

Publication bias and p-hacking diagnosis

funnel plot

Funnel plot not drawn. Less than 3 points.

Asymetry test p-value = NaN (by Egger's regression)

not enought points

p values plot

Funnel plot not drawn. Less than 3 points.

Sub-groups analysis using all included studies

excluded 16795, 19436

Sub-groupsTE95% CIn casesn exposedkI2ROB type of controls unexposed, sick controlsunexposed, sick controls 0.94[0.33; 2.70]8298661%NAHonybun (Controls unexposed, sick) (Topiramate) (Epilepsy), 2026 Straub (Controls unexposed, sick) (Topiramate) (Epilepsy), 2026 Thomas b (Controls unexposed, sick), 2022 3 exposed to other treatment, sick controlsexposed to other treatment, sick controls 1.83[0.66; 5.09]-170%NAHonybun (Controls exposed to LTG) (Topiramate) (Epilepsy), 2026 Thomas b (Controls exposed to LTG), 2022 20.510.01.0